Sources: FactSet, Dow Jones, ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. Returns as of 10/10/2020. 2 Big Biotech Stock Upgrades: Can They Reach These Targets? Stock Advisor launched in February of 2002. Source: FactSet. 4 Disruptive Healthcare Stocks You've Never Heard Of, Copyright, Trademark and Patent Information. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California. The phase 1 trial is evaluating a combination of cell therapy drug candidate ALLO-501 and monoclonal antibody drug candidate ALLO-647 to treat advanced non-Hodgkin lymphoma (NHL). Perhaps investors are increasingly considering the potential for a buyout from a larger pharmaceutical company, but the valuation does appear to price in a lot of future success. Change value during the period between open outcry settle and the commencement of the next day's trading is calculated as the difference between the last trade and the prior day's settle. Sources: CoinDesk (Bitcoin), Kraken (all other cryptocurrencies), Calendars and Economy: 'Actual' numbers are added to the table after economic reports are released. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Nonetheless, today's news is encouraging for existing shareholders. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization... Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Currency in USD. Source: FactSet Fundamentals. Maxx has been a contributor to Fool.com since 2013. Additional results are expected to be reported at the virtual ASCO meeting at the end of May. Sources: FactSet, Tullett Prebon, Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange requirements. Allogene Therapeutics is now valued at $5 billion. For the phase 1 study in the news today, ALLO-501 is an allogeneic cell therapy designed to target blood cancer cells, while ALLO-647 is a monoclonal antibody that depletes lymphocytes to prepare a patient's body for CAR-T treatment. Perhaps investors are increasingly considering the potential for a buyout from a larger pharmaceutical … The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Mutual Funds & ETFs: All of the mutual fund and ETF information contained in this display, with the exception of the current price and price history, was supplied by Lipper, A Refinitiv Company, subject to the following: Copyright 2020© Refinitiv. Burr, Senate Colleagues Sold Stock After Coronavirus Briefings, Pinterest, Zoom Shares Surge in Trading Debuts, Biotechs With No Drugs in Trial Are Raising Millions in IPOs, Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation, Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation, Allogene Therapeutics Reports Second Quarter 2020 Financial Results, Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020, Notch Therapeutics Appoints David Main as President and Chief Executive Officer to Advance the Company's Novel Gene-Edited, iPSC-Derived Immune Cell Therapeutics, Vanguard US Total Market Shares Index ETF, American Funds Insurance Series - Global Small Cap Fund, Capital Research & Management Co. (Global Investors), Capital Research & Management Co. (International Investors), Capital Research & Management Co. (World Investors), T. Rowe Price Associates, Inc. (Investment Management). It also supports the broad use of ALLO-647 as a next-generation lymphodepletion agent, which is required for many types of cancer therapies. © 2020 Verizon Media. Allogene Therapeutics, Inc.’s ISS Governance QualityScore as of October 6, 2020 is 9. 210 East Grand AvenueSouth San Francisco, CA 94080United States650 457 2700http://www.allogene.com, Sector(s): HealthcareIndustry: BiotechnologyFull Time Employees: 236. View today's stock price, news and analysis for Allogene Therapeutics Inc. (ALLO). Cryptocurrencies: Cryptocurrency quotes are updated in real-time. Allogene intends to assume from Pfizer the global strategic collaboration agreement originally formed with Cellectis in 2014. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. All rights reserved. As of 12:42 p.m. EDT, the pharma stock had settled to a 30.2% gain. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. The ASCO abstract from Allogene Therapeutics showcases results from a dose escalation study, which means researchers are administering the experimental combination therapy at different doses to determine the optimal balance of safety and efficacy. The results were generated from just nine patients treated at the lower dose of ALLO-647. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. Change value during other periods is calculated as the difference between the last trade and the most recent settle. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Allogene Therapeutics, Inc. operates as a biotechnology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk. About Allogene Therapeutics Inc Allogene Therapeutics, Inc. operates as a biotechnology company. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) therapies for cancer. Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Unlike first-generation cell CAR-T therapies, allogeneic cell therapies are derived from donors or cell lines, which allows them to be manufactured at significantly lower cost and larger scale.

Rt Podcast Mush, Anderson V Milbank, Ben Nicholson Sri Lanka, The Story Of The Last Supper, How To Get Ahead In Advertising Youtube, Art And Morality Quotes, Ac-50 Delhi,